Released May 7, 2020, after the close
10-Q filed May 8, 2020, 38 days after period end · 0001564590-20-023566
Q1 2020 · 10-Q
Revenue$4.08M$4.08M +5.0% vs Q1 2019−14.4% vs Q4 2019
Net Income-$26.66M-$26.66M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.76-$0.76 N/M vs Q1 2019N/M vs Q4 2019
Operating Income-$27,694,000N/M
Operating Cash Flow-$25,218,000N/M
Free Cash Flowderived-$25,283,000N/M
Margins · derived
Operating margin-678.6%+50.8 pt vs Q1 2019
Net margin-653.1%+43.2 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $4.08M | $3.89M | $3.57M | $684.00K |
| Net Income | -$26.66M | -$27.05M | -$16.25M | -$13.93M |
| EPS Diluted | -$0.76 | -$1.05 | -$0.80 | -$810.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR